Close Menu

NEW YORK ─ Avalon GloboCare said Monday that it has entered a strategic partnership with Beijing-based genetic testing services provider GensKey Medical Technology to codevelop and commercialize point-of-care antibody and PCR tests for SARS-CoV-2.

Both the antibody- and PCR-based tests have received the CE-IVD mark and are pending US Food and Drug Administration Emergency Use Authorization, Avalon said.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.